**Suggested citation:** EFSA CEP Panel (EFSA Panel on Food Contact Materials, Enzymes and Processing Aids) , Silano V, Barat Baviera JM, Bolognesi C, Brüschweiler BJ, Chesson A, Cocconcelli PS, Crebelli R, Gott DM, Grob K, Lampi E, Mortensen A, Steffensen I‐L, Tlustos C, Van Loveren Henk, Vernis L, Zorn H, Castle L, Cravedi J‐P, Franz R, Kolf‐Clauw M, Milana MR, Pfaff K, Svensson K, Tavares Poças MF, Wölfle D, Volk K and Rivière G, 2019 Safety assessment of the substance poly((*R*)‐3‐hydroxybutyrate‐co‐(*R*)‐3‐hydroxyhexanoate) for use in food contact materials. EFSA Journal 2019;17(1):5551, 12 pp. 10.2903/j.efsa.2019.5551

**Requestor:** Ministry of Health, Welfare and Sports; The Netherlands

**Question number:** EFSA‐Q‐2017‐00412

**Panel members:** José Manuel Barat Baviera, Claudia Bolognesi, Beat Johannes Brüschweiler, Andrew Chesson, Pier Sandro Cocconcelli, Riccardo Crebelli, David Michael Gott, Konrad Grob, Evgenia Lampi, Alicja Mortensen, Gilles Rivière, Vittorio Silano, Inger‐Lise Steffensen, Christina Tlustos, Henk Van Loveren, Laurence Vernis, Holger Zorn.

**Acknowledgements:** The CEP Panel wishes to thank the WG on Food Contact Materials of the former EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) for the preparatory work on this scientific output.

**Note:** The full opinion will be published in accordance with Article 10(6) of Regulation (EC) No 1935/2004 once the decision on confidentiality, in line with Article 20(3) of the Regulation, will be received from the European Commission. The following information has been provided under confidentiality and it is redacted awaiting the decision of the Commission: results of migration testing (food simulant E) of reaction products and/or residuals from the starting substance; report on fluid tests simulating gastric and intestinal pH conditions.

Adopted: 5 December 2018

This output supersedes two previous scientific opinions on the Safety assessment of the substance Poly((R)‐3‐hydroxybutyrate‐co‐(R)‐3‐hydroxyhexanoate) for use in food contact materials (<https://doi.org/10.2903/j.efsa.2016.4464> and <https://doi.org/10.2903/j.efsa.2018.5326>).

1. Introduction {#efs25551-sec-0002}
===============

1.1. Background and Terms of Reference as provided by the requestor {#efs25551-sec-0003}
-------------------------------------------------------------------

Before a substance is authorised to be used in food contact materials (FCM) and is included in a positive list EFSA\'s opinion on its safety is required. This procedure has been established in Articles 8, 9 and 10 of Regulation (EC) No 1935/2004[1](#efs25551-note-1008){ref-type="fn"} of the European Parliament and of the Council of 27 October 2004 on materials and articles intended to come into contact with food.

According to this procedure, the industry submits applications to the Member States' competent authorities which transmit the applications to EFSA for their evaluation.

In this case, EFSA received an application from the Ministry of Health, Welfare and Sport, the Netherlands, requesting the evaluation of the substance poly((*R*)‐3‐hydroxybutyrate‐co‐(*R*)‐3‐hydroxyhexanoate), with the Chemical Abstracts Service (CAS) number 147398‐31‐0, and the FCM substance No 1059. The dossier was submitted by TNO Triskelion BV on behalf of Kaneka Belgium N.V.

According to Regulation (EC) No 1935/2004 of the European Parliament and of the Council on materials and articles intended to come into contact with food, EFSA is asked to carry out an assessment of the risks related to the intended use of the substance and to deliver a scientific opinion.

2. Data and methodologies {#efs25551-sec-0004}
=========================

2.1. Data {#efs25551-sec-0005}
---------

The applicant has submitted a dossier in support of his application for the authorisation of poly((*R*)‐3‐hydroxybutyrate‐co‐(*R*)‐3‐hydroxyhexanoate) (PHBH) to be used in FCM in contact with all kinds of food. Information provided in this dossier was already taken into consideration for a previous evaluation of the substance for use in contact with dry foods (EFSA CEF Panel, [2018](#efs25551-bib-0005){ref-type="ref"}), as requested by the European Commission in June 2017 (EFSA‐Q‐2017‐00495). The current evaluation reflects, as requested by the applicant, the use of the substance with all foods, therefore including the previously assessed use with dry foods.

Additional information was provided by the applicant during the assessment process in response to requests from EFSA sent on 12 July 2017[2](#efs25551-note-1009){ref-type="fn"}, 20 October 2017[3](#efs25551-note-1010){ref-type="fn"}, 20 December 2017[4](#efs25551-note-1011){ref-type="fn"} and 4 June 2018[4](#efs25551-note-1011){ref-type="fn"} (see 'Documentation provided to EFSA').

Following the requests for additional data sent by EFSA on 20 October 2017, 20 December 2017 and 04 June 2018, the applicant requested clarification teleconferences, which were held on 10 November 2017, 09 March 2018 and 19 June 2018.

Data submitted and used for the evaluation are:

**Non‐toxicological data and information** Chemical identityDescription of manufacturing process of substance/FCMPhysical and chemical propertiesIntended useExisting authorisation(s)Identification, quantification and migration of oligomers, reaction products and impurities.

**Toxicological data** Bacterial gene mutation tests*In vitro* mammalian cell gene mutation test*In vivo* mouse bone marrow micronucleus testrepeated dose 90‐day oral toxicity study in ratsFluid tests simulating gastric and intestinal pH conditionsInformation on accumulation in rats.

2.2. Methodologies {#efs25551-sec-0006}
------------------

The assessment was conducted in line with the principles laid down in Regulation (EC) No 1935/2004 on materials and articles intended to come into contact with food. This Regulation underlines that applicants may consult the Guidelines of the Scientific Committee on Food (SCF) for the presentation of an application for safety assessment of a substance to be used in FCM prior to its authorisation (European Commission, [2001](#efs25551-bib-0006){ref-type="ref"}), including the corresponding data requirements. The dossier that the applicant submitted for evaluation was in line with the SCF guidelines (European Commission, [2001](#efs25551-bib-0006){ref-type="ref"}).

The methodology is based on the characterisation of the substance that is the subject of the request for safety assessment prior to authorisation, its impurities and reaction and degradation products, the evaluation of the exposure to those substances through migration and the definition of minimum sets of toxicity data required for safety assessment.

To establish the safety from ingestion of migrating substances, the toxicological data indicating the potential hazard and the likely human exposure data need to be combined. Exposure is estimated from studies on migration into food or food simulants and considering that a person may consume daily up to 1 kg of food in contact with the relevant FCM.

As a general rule, the greater the exposure through migration, the more toxicological data is required for the safety assessment of a substance. Currently, there are three tiers with different thresholds triggering the need for more toxicological information as follows: In case of high migration (i.e. 5--60 mg/kg food), an extensive data set is needed.In case of migration between 0.05 and 5 mg/kg food, a reduced data set may suffice.In case of low migration (i.e. \< 0.05 mg/kg food), only a limited data set is needed.

More detailed information on the required data is available in the SCF guidelines (European Commission, [2001](#efs25551-bib-0006){ref-type="ref"}).

The assessment was conducted in line with the principles described in the EFSA Guidance on transparency in the scientific aspects of risk assessment (EFSA, [2009](#efs25551-bib-0001){ref-type="ref"}) and considering the relevant guidance from the EFSA Scientific Committee.

3. Assessment {#efs25551-sec-0007}
=============

According to the applicant, the substance PHBH, CAS No 147398‐31‐0, is a biodegradable copolymer. It is intended to be used as such or compounded with other bio‐based/biodegradable materials, such as starch, polylactic acid, polybutyrate adipate terephthalate and polybutylene succinate, to produce packaging articles like bags and trays at a maximum process temperature of 200°C. The articles are intended to be in contact with all kinds of food for long‐term storage, i.e. 6 months or more at room temperature or below, including possible hot‐fill or short heating up conditions.

3.1. Non‐toxicological data {#efs25551-sec-0008}
---------------------------

### 3.1.1. Physical and chemical properties {#efs25551-sec-0009}

Chemical formula: H\[C~4~H~6~O~2~\]~x~\[C~6~H~10~O~2~\]~y~OH (Figure [1](#efs25551-fig-0001){ref-type="fig"})

![Chemical structure of poly((*R*)‐3‐hydroxybutyrate‐co‐(*R*)‐3‐hydroxyhexanoate)](EFS2-17-e05551-g001){#efs25551-fig-0001}

The substance PHBH is produced by fermentation of palm oil and/or palm oil fatty acid distillate as carbon source using a genetically modified microorganism (*Cupriavidus necator*). It consists of 80--99% 3‐hydroxybutyrate (3HB) and 1--20% 3‐hydroxyhexanoate (3HH). Before isolating the copolymer, the microorganisms are inactivated by heat treatment. The purity is higher than 98%. The molecular weight (Mw) ranges from 10,000 to 1,000,000 Da with Mw = 518,000 Da, number average molecular weight (Mn) = 182,000 Da. The fraction below 1,000 Da amounts to 0.5%.

The substance has a melting point ranging from 120 to 150°C, depending on the monomeric composition. It is virtually insoluble in water and ethanol and is sparingly soluble in toluene, chloroform and tetrahydrofuran (THF). It is prone to dehydration at high temperature as well as to both dehydration and partial hydrolysis in aqueous media.

### 3.1.2. Migration studies {#efs25551-sec-0010}

Since the carbon source for the fermentation is palm oil, which is listed as FCM substance No 9 under Regulation (EU) No 10/2011 without a specific restriction, specific migration of this starting substance was not tested.

In accord with the intended use in contact with all food types, migration tests were conducted with simulant E (modified polyphenylene oxide, for dry foods), 10% ethanol (for water and aqueous foods), 3% acetic acid (for acidic foods) as well as olive oil, isooctane and 95% ethanol (for fatty foods). A range of time and temperature conditions were used, up to and including 10 days contact at 60°C. All migration tests used a polymer containing 89 mol% of 3HB and 11 mol% of 3HH.

Overall migration into 10% ethanol, 3% acetic acid and olive oil (each for 10 days/60°C) was respectively 5.4, 3.0 and not detectable (\< 6 mg/kg). The overall migration into isooctane (10 days/60°C) and 95% ethanol (10 days/20°C) was much higher at 41 and 17 mg/kg. It was concluded that these alternative food simulants, isooctane and 95% ethanol, are not appropriate for this type of polar polyester and that the intended food contact uses are adequately covered by the other simulants used. Of all the liquid food simulants used, the 10% ethanol simulant was considered to be the most representative.

Overall migration was not determined using the dry powder simulant E, but it is expected to be low. This simulant is especially diagnostic for testing the migration of volatile and semi‐volatile substances. The migration extracts from the simulant E test (10 days/40°C) were analysed by gas chromatography--mass spectrometry (GC--MS) in order to investigate the presence and identity of other migrants, such as residuals from the starting substance or reaction products. Assuming uniform response factors for their semi‐quantification, the following migrants and migration levels were found: ■■■■■ These substances were concluded to originate from or to be likely related to the source material 'palm oil and/or palm fatty acid distillate' already authorised under Regulation (EU) No 10/2011.

The polymer end‐groups can be dehydrated by heating and/or acid/base‐catalysed reaction when the polymer is heated for processing into films and sheets or exposed to aqueous foods/simulants.

A minor reaction pathway for dehydration is the formation of free crotonic acid ((*E*)‐2‐butenoic acid) and (*E*)‐2‐hexenoic acid. Crotonic acid is listed in Regulation (EU) No 10/2011 under FCM substance No 467 with a specific migration limit (SML) of 0.05 mg/kg food; (*E*)‐2‐hexenoic acid is listed as flavouring in Regulation (EC) No 872/2012 under \[FL‐no: 08.119\]. In all migration tests conducted (simulant E, 3% acetic acid, 10% ethanol and olive oil), the migration of crotonic acid was below its SML. From the ratio of C4 to C6 units in the copolymer and assuming equal susceptibility to dehydration, the hexenoic acid should migrate at lower concentrations than crotonic acid.

The 10% ethanol migration solutions, analysed using liquid chromatography--mass spectrometry (LC--MS) analysis, revealed a range of hydroxyl (OH‐)‐terminated (i.e. unchanged) and crotyl‐terminated (i.e. dehydrated) oligomers from the dimer (n = 2) up to the limit of the MS scan range used (n = 12, Mw 1,050 for OH‐terminated, Mw 1,032 for crotyl‐terminated). The smaller oligomers (dimers, trimers, tetramers and pentamers) dominated in the 10% ethanol migration solution, particularly on the molar basis. Assuming a uniform molar MS response and correcting the MS response for the Mw, the OH‐terminated oligomers were in the following proportions on a w/w basis: n = (1--4) at 25.8%, n = (1--5) at 43.0%, n = (1--6) at 50.9%. The crotyl‐terminated oligomers were in the following proportions: n = (1--4) at 21.6%, n = (1--5) at 31.4% and n = (1--6) at 36.1%. The migration of all oligomers ≤ 1,000 Da, n = (1--11), was 59.8% hydroxyl‐ and 40.0% crotyl‐terminated. The pentamers (Mw of 448 (OH‐) or 430 (crotyl‐)) were used as cut‐off for characterising the 10% ethanol migrate, with 43.0% (OH‐) and 31.4% (crotyl‐) meaning that 74.4% of the total oligomer migration were oligomers \< 500 Da.

The applicant attempted to quantify the LC--MS results using 3‐hydroxybutyric acid as a calibrant and assuming that the oligomers had the same response. This was unsuccessful because the sum of oligomers resulted about 10 times the overall migration value, which is not possible. The Panel decided, therefore, to scale the oligomer results using the overall migration value. For the 10% ethanol simulant the overall migration was 5.4 mg/kg. On this basis, the migration into 10% ethanol of oligomers up to and including the pentamer (i.e. Mw \< 500 Da) is estimated to be 2.3 mg/kg of OH‐terminated and 1.7 mg/kg of crotyl‐terminated oligomers.

In reality, a substantial part of the oligomers contains at least one 3HH unit and 11% of the end groups were probably 3HH and hexenoyl units in the same proportion as crotyls among the 3HB terminal units. As this has no effect on the comparison with the synthetic mixture used for toxicity testing (see Section [3.1.3](#efs25551-sec-0011){ref-type="sec"}), this aspect was not elaborated further.

### 3.1.3. Preparation and characterisation of the oligomer mix used in toxicity studies {#efs25551-sec-0011}

The substance (containing 11 mol% 3HH) was dissolved in hot aqueous acetonitrile and hydrolysed with sulfuric acid. After neutralisation and evaporation of the solvent, an oligomer mixture was obtained as a white precipitate. This mixture was analysed by ^1^H‐nuclear magnetic resonance (^1^H‐NMR) and ^13^C‐NMR spectroscopy. It revealed OH‐terminated oligomers with a varying number of 3HB and 3HH repeated units. No alkene groups, i.e. dehydrated end groups, were detected. The 3HH content was 11.9 mol%. The molecular weight estimated by gel permeation chromatography (GPC) was Mw = 2,000 Da; Mn: 1,050 Da, the fraction ≤ 1,000 Da 30%. LC--MS analysis found 15 PHBH oligomer peaks, of which 11 being \< 1,000 Da. The applicant noted that LC--MS (using the atmospheric pressure chemical ionisation (APCI) technique) is not generally capable of detecting oligomers above \~ 1,000 Da. The smallest oligomer was a hexamer with a molecular weight of 535 Da.

As described above, in the 10% ethanol migration solutions, substantial amounts of crotyl‐terminated oligomers were present and the migrating oligomers were predominantly dimers, trimers and tetramers, i.e. with molecular weights considerably lower than the smallest oligomer identified in the oligomer mixture used for the toxicity studies. Therefore, its representativeness was questionable and so the applicant provided data on simulated gastric and intestinal stability tests.

■■■■■

The LC--MS data were treated using the same assumptions as described above for the migration studies and corrected for the fact that 70% of the original oligomer mix was \> 1,000 Da, i.e. outside of the range covered by the LC--MS analysis. Then, the oligomer mix after simulated gastric treatment had the following composition on a w/w basis: the OH‐terminated oligomers were ■■■■■; the crotyl‐terminated oligomers were ■■■■■. Hence, the mixture contained ■■■■■ OH‐terminated and ■■■■■ crotyl‐terminated oligomers ≤ 1,000 Da (n = (1--11). As discussed above, the oligomers up to the pentamers were considered characteristic for the 10% ethanol migrates. The gastric‐treated oligomers had a ■■■■■ content of OH‐terminated oligomers and ■■■■■ crotyl‐terminated oligomers than the migrate into 10% ethanol. If the oligomers ≤ 1,000 Da, n = (1--11), were used for the comparison, the corresponding figures would be ■■■■■ and ■■■■■ for the OH‐ and crotyl‐terminated oligomers, respectively.

The specific masses for the 3HH‐containing oligomers were not looked for in this LC--MS analysis. As was done above for the 10% ethanol migrate, the Panel assumes that the oligomer mix after simulated gastric treatment, contains 3HH‐units pro‐rata to the polymer composition, being 11 mol% for the sample prepared and confirmed (at 11.9 mol%) by the NMR analysis.

3.2. Microbiological information {#efs25551-sec-0012}
--------------------------------

Given the heat treatment and the applied purification steps at the end of the production process and the heat treatment during manufacturing of the final FCM, the use of *Cupriavidus necator* as a producing organism is considered to be of no safety concern.

3.3. Toxicological data {#efs25551-sec-0013}
-----------------------

### 3.3.1. Evaluation of the substance itself {#efs25551-sec-0014}

No genotoxicity data are required for PHBH as the substance is a large polymer with a molecular weight ranging between 10,000 and 1,000,000 Da, which are unlikely to be absorbed in the gastrointestinal tract. Nevertheless, the applicant provided a complete set of genotoxicity tests, i.e. a bacterial reverse mutation test, an *in vitro* mammalian chromosome aberration test and an *in vivo* micronucleus bone marrow test. The *in vitro* tests were negative but limited due to the precipitation of the compound in the culture medium. No increase in micronuclei frequency was observed in the *in vivo* test in mice, but no evidence was provided for the exposure of the bone marrow. The fraction below 1,000 Da amounts to 0.5%, with the major part being above 500 Da.

Nevertheless, the Panel noted that the major unit of this polymer, 3‐hydroxybutyric acid, is an intermediate in fatty acid metabolism. For the minor unit of this polymer, 3‐hydroxyhexanoic acid, a bacterial reverse mutation test according to OECD TG471 was provided. It was tested for gene mutation in four histidine‐requiring strains TA98, TA100, TA1535 and TA1537 of *Salmonella* Typhimurium, and in *Escherichia* coli strain WP2 uvrA both in the absence and in the presence of metabolic activation up to 5,000 μg/plate. The results of the study were considered negative.

### 3.3.2. Evaluation of the migrating oligomers {#efs25551-sec-0015}

The PHBH oligomer mixture, synthesized as described above to simulate the migration mixture into 10% ethanol, was tested in a basic battery of genotoxicity tests, i.e. a bacterial reverse mutation test, an *in vitro* mammalian cell gene mutation test, and an *in vitro* mammalian chromosome aberration test, and in a repeated dose 90‐day oral toxicity study. As derived above, even after simulated gastric treatment, the composition of the synthesized oligomers deviated substantially from that of the oligomers in the 10% ethanol migrate, both in terms of molecular mass distribution and proportion of crotyl‐terminated species. The data of the toxicological experiments were nonetheless considered and evaluated together with other facts.

A bacterial reverse mutation (Ames) test (plate incorporation method) with the PHBH oligomer was conducted according to OECD guideline 471 and in compliance with Good laboratory practice (GLP) guidelines. *S. *Typhimurium strains TA1535, TA1537, TA98, TA100 and *E. coli* strain WP2 uvrA were used in the absence and presence of metabolic activation (S9‐mix). The test substance PHBH oligomer was dissolved in dimethyl sulfoxide (DMSO). A single experiment was performed in triplicate at the concentrations: 62, 185, 556, 1,667 and 5,000 μg/plate. No cytotoxicity was observed at any bacterial strain tested up to 5,000 μg/plate. A dose‐related precipitation was observed at and above a concentration of 556 μg/plate. The test substance did not induce statistically significant increase in the mean number of revertant colonies compared to the background spontaneous reversion rate observed with the negative control in any bacterial strain tested both in the absence and presence of S9‐mix.

An *in vitro* mammalian cell gene mutation test at the TK‐locus of cultured mouse lymphoma L5178Y cells in the absence and presence of metabolic activation (S9‐mix) was carried out according to OECD guideline 490 and in compliance with GLP. The PHBH oligomer mixture was dissolved in DMSO. The maximum final concentration of PHBH oligomer (800 μg/mL) was limited by solubility of the test substance in culture medium. No cytotoxicity was observed after 4 and 24 h treatment in the presence of S9‐mix and 24 h in the absence of S9‐mix. Following 4 h treatment in the absence of S9‐mix, the test substance PHBH oligomer was found to be cytotoxic at the highest concentration tested. No increase in mutant frequency (MF) compared to the negative control was observed at any of the dose levels tested both in the absence and presence of S9‐mix.

An *in vitro* mammalian chromosome aberration test in cultured human primary lymphocytes in the absence and presence of S9‐mix was conducted according to OECD guideline 473 and in compliance with GLP. The PHBH oligomer mixture was dissolved in DMSO. In the first experiment at 4 h in the presence and absence of S9‐mix, the concentrations tested were: 25, 100, 400 and 800 μg/mL. In the second test at 24 h in the absence of S9‐mix the cells were treated at 50, 200 and 400 μg/mL. The maximum final concentration of PHBH oligomer (800 μg/mL) was limited by solubility of the test substance in culture medium. Precipitation was observed at 800 μg/mL for all tests and at 400 μg/mL in the presence of metabolic activation. Cytotoxicity at 4 h with and without S9‐mix and at 24 h with S9‐mix was observed at the highest concentration tested. At 24 h treatment in the absence of S9‐mix a dose‐related increase of cytotoxicity was reported. The test substance did not induce a statistically significant increase in the number of aberrant cells, at any of the concentrations and treatment periods compared to solvent control cultures.

In conclusion, the PHBH oligomer mixture is not mutagenic in bacteria and mammalian cells and not clastogenic in human lymphocytes. Considering that the representativeness of the PHBH oligomer mixture tested is questionable, SAR predictions for possible genotoxic activity of OH‐ and crotyl‐terminated 3HB dimers were also assessed. An '*in silico* prediction' for gene mutation and chromosomal damage was made with the knowledge based 'Derek Nexus': no alerts for gene mutation or chromosomal damage were reported.

The Panel concluded that the PHBH migrating oligomers do not give rise to concern for genotoxicity.

A repeated dose 90‐day oral toxicity study in rats (Wistar Han IGS rats (Crl:WI(Han)) was conducted according to OECD guideline 408 and in compliance with GLP. The study comprised four groups of 10 rats/sex. Three test groups received the test substance added to diet at levels of 0.25%, 0.75% and 2.25% and a control group (0%) received the diet only. These dietary levels provided an overall mean intake of the test substance in the low‐, mid‐ and high‐dose group of 151, 449 and 1,364 mg PHBH oligomer/kg body weight (bw) per day for males, and 165, 519 and 1,501 mg PHBH oligomer/kg bw per day for females, respectively.

There was no mortality and there were no treatment‐related clinical signs. Behavioural endpoints (functional observation battery and motor activity assessment) did not indicate any neurotoxic potential of the test substance. Ophthalmoscopy did not reveal any treatment‐related ocular changes. There were no treatment‐related changes in body weight, food intake or water intake.

Clinical chemistry, conducted on all rats at necropsy, did not reveal any treatment‐related changes. Urinalysis was conducted on all rats in the week prior to necropsy. The renal concentrating ability was not affected and microscopic examination of the urinary sediment did not reveal any treatment‐related effects.

Haematology was conducted on all rats at necropsy. There were no relevant changes in red blood cell variables or in total and differential white blood cell counts. Thrombocytes were slightly (8.5%), though statistically significantly, decreased in high‐dose males. No biological significance was attributed to this finding because the values were well within the range of historical control data.

No treatment‐related differences in absolute organ weights or in organ‐to‐body weight ratios were observed. The relative weight of the adrenals was slightly, though statistically significantly, increased in males of the low‐dose and high‐dose groups. The effect was not considered relevant because there was no dose--response relationship and the values were well within the range of historical control data. Macroscopic examination at necropsy and microscopic examination of organs and tissues did not reveal treatment‐related findings.

The Panel identified the no‐observed‐adverse‐effect level (NOAEL) at the highest level tested in males, 1,364 mg/kg bw per day.

The systemic availability of PHBH oligomer in plasma, liver tissue and peri‐renal fat tissue was evaluated in five rats/sex per group by LC--MS. The test substance could not be detected in plasma (lower limit of quantification (LLOQ) = 1 μg/mL) and did not accumulate in liver tissue or peri‐renal fat tissue (LLOQ = 2 μg/g). These results suggest that the potential for bioaccumulation is low.

The Panel considered the oligomer mixture used in the toxicity studies as sufficiently similar to the migrating oligomers because: (i) simulated gastric and/or intestinal treatment brings the composition closer to that of the migrate; (ii) the lower content of small oligomers can be compensated by using a correction factor (CF). A factor of 20 was used as it covers both the OH‐terminated oligomers ■■■■■ and the crotyl‐terminated oligomers ■■■■■. This factor was considered conservative because if the total oligomer content ≤ 1,000 Da had been used for the comparison, the corresponding factors would be ■■■■■ and ■■■■■ for the OH‐ and crotyl‐terminated oligomers, respectively.

There was no adverse effect seen in rats at the highest dose used in the repeated dose 90‐day oral toxicity study, 1,364 mg/kg bw per day. If, by way of illustration, this dose is reduced by a factor of 20 to account for the low molecular weight OH‐ and crotyl‐terminated oligomers, it corresponds to 68.2 mg/kg bw per day. According to the tiered approach (European Commission, [2001](#efs25551-bib-0006){ref-type="ref"}), the toxicological data provided could support a SML on the oligomers of 5 mg/kg food. Taking the conventional assumptions, this SML would correspond to an exposure of 0.083 mg/kg bw per day. Compared to the corrected NOAEL of 68.2 mg/kg bw per day, this would give a Margin of Exposure (MoE) of 822. Taking account of the facts that the true NOAEL is likely to be higher, the correction factor is conservative and considering the nature of the polyester oligomers and their hydroxy acid constituents, this MoE is concluded to be adequate. Any restriction on the migration of oligomers should relate to the whole oligomer fraction \< 1,000 Da.

### 3.3.3. Evaluation of the migrating impurities {#efs25551-sec-0016}

According to the migration studies with the food simulant E, several substances were found to migrate and it was concluded that they originate or are likely related to the already authorised substance (FCM substance No 9) 'palm oil and/or palm fatty acid distillate' used as a carbon source for the fermentation. Given the nature and origin of these substances, their migration at the levels reported does not give rise to a safety concern.

### 3.3.4. Evaluation of the dehydration products {#efs25551-sec-0017}

As noted above, a minor reaction pathway for dehydration is the formation of free crotonic acid ((*E*)‐2‐butenoic acid) and (*E*)‐2‐hexenoic acid. Also, if oligomers that are terminated with either of these alkenes are hydrolysed (*in vivo* or *ex vivo*) then further exposure to crotonic acid and/or (*E*)‐2‐hexenoic acid could occur.

Several crotonate esters are used as flavouring substances and have been evaluated by EFSA (EFSA CEF Panel, [2010a](#efs25551-bib-0002){ref-type="ref"}). When the alcohol moiety is a simple alkyl (i.e. methyl crotonate \[FL‐no: 09.636\], propyl crotonate \[FL‐no: 09.699\], and isopropyl crotonate \[FL‐no: 09.603\]), they were classified as structural class I, so having a threshold of concern of 1,800 μg/person per day. Furthermore, they were evaluated by Flavouring Group Evaluation (FGE) procedure Path A meaning that the crotonate esters can be predicted to be metabolised to innocuous products (EFSA CEF Panel, [2010a](#efs25551-bib-0002){ref-type="ref"}). The normal use levels of these crotonate ester flavouring substances, as indicated by industry, were 2--20 mg/kg food and the maximum use levels indicated were in the range of 100 mg/kg food. At that time the former EFSA CEF Panel noted that: 'Crotonic acid \[FL‐no: 08.072\], which is the hydrolysis product of several of the candidate esters, has been evaluated by the SCF (SCF_list 3; Limit of migration: 50 microgram/kg food, based on the reduced core set of toxicological data according to the migration level \[SCF, 2002a\]'. The former EFSA CEF Panel ([2010a](#efs25551-bib-0002){ref-type="ref"}) noted that this migration limit for crotonic acid could apparently conflict with reported use levels of the crotonates as flavouring substances. 'However, the migration limit is set after administrative considerations (limited data submitted) rather than on toxicological data, and the Panel therefore did not find the low migration limit for crotonic acid as such in conflict with higher use levels of the crotonates, which could therefore go through the Procedure'.

Similar to the crotonates, (*E*)‐2‐hexenoic acid \[FL‐no: 08.119\] has been evaluated by EFSA (EFSA CEF Panel, [2010b](#efs25551-bib-0003){ref-type="ref"}) as a flavouring substance. It was classified into structural class I and predicted to be metabolised to innocuous products. Hence, it was evaluated via the A‐side of the FGE Procedure (EFSA CEF Panel, [2010b](#efs25551-bib-0003){ref-type="ref"}). The normal and maximum use levels were not provided by Industry for \[FL‐no: 08.119\]. However, it is noteworthy that in the whole group of 37 substances covered in the evaluation, \[FL‐no: 08.119\] had by far the highest calculated Maximised Survey‐derived Daily Intake (MSDI) value at 240 μg/person per day. The MSDI value is an estimate of exposure calculated from production volumes of the flavouring substance. The MSDI is accepted to be an underestimate (sometimes, a very large underestimate) of the exposure of individuals.

The same is the case for ethyl *trans*‐2‐hexenoate, taken here as an example of a simple alkyl ester of the unsaturated acid. It is \[FL‐no: 09.850\] and was classified into structural class I, predicted to be metabolised to innocuous products, and evaluated via the A side. The MSDI value derived was 21 μg/person per day (EFSA CEF Panel, [2010c](#efs25551-bib-0004){ref-type="ref"}).

These considerations lead the CEP Panel to the conclusion that the potential migration of crotonic acid ((*E*)‐2‐butenoic acid) and (*E*)‐2‐hexenoic acid, and the content of these two substances bound into the oligomer chains but likely to be released by hydrolysis following migration and ingestion, does not give rise to a safety concern.

4. Conclusions {#efs25551-sec-0018}
==============

The CEP Panel, based on the above‐mentioned data, concluded that the substance PHBH is not of safety concern for the consumer if it is used either alone or blended with other polymers in contact with all kinds of food, under contact conditions of more than 6 months at room temperature or below, including hot‐fill or a short heating up phase. The specific migration of all oligomers \< 1,000 Da should not exceed 5 mg/kg food. The migration of the degradation product crotonic acid should not exceed the existing SML of 0.05 mg/kg food. As the migration of (*E*)‐2‐hexenoic acid can be expected to be always lower than that of crotonic acid, no individual restriction is necessary.

Documentation provided to EFSA {#efs25551-sec-0019}
==============================

poly((*R*)‐3‐hydroxybutyrate‐co‐(*R*)‐3‐hydroxyhexanoate). May 2017. Submitted by TNO Triskelion BV on behalf of Kaneka Belgium N. V.Additional data (in relation to EFSA‐Q‐2017‐00495). August 2017. Submitted by Kaneka Belgium N. V.Additional data (in relation to EFSA‐Q‐2017‐00412). November 2017. Submitted by Kaneka Belgium N. V.Additional data (in relation to EFSA‐Q‐2017‐00495). March 2018. Submitted by Kaneka Belgium N. V.Additional data (in relation to EFSA‐Q‐2017‐00412). March 2018. Submitted by Kaneka Belgium N. V.Additional data (in relation to EFSA‐Q‐2017‐00412). September 2018. Submitted by Kaneka Belgium N. V.

Abbreviations {#efs25551-sec-0020}
=============

APCIatmospheric pressure chemical ionisationbwbody weightCASChemical Abstracts ServiceCEP PanelEFSA Panel on Food Contact Materials, Enzymes and Processing AidsCEF PanelEFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing AidsCFCorrection factorDMSOdimethyl sulfoxideFCMfood contact materialsGCgas chromatographyGLPGood laboratory practiceGPCgel permeation chromatographyFGEFlavouring Group EvaluationHBhydroxybutyrateHHhydroxyhexanoateLCliquid chromatographyLLOQlower limit of quantificationMFmutant frequencyMnnumber average molecular weightMoEMargin of exposureMSmass spectrometryMSDIMaximised Survey‐derived Daily IntakeMwmolecular weightNMRnuclear magnetic resonanceNOAELno‐observed‐adverse‐effect levelOECDOrganisation for Economic Co‐operation and Development PHBHpoly((*R*)‐3‐hydroxybutyrate‐co‐(*R*)‐3‐hydroxyhexanoate)SCFScientific Committee on FoodSMLspecific migration limitTHFtetrahydrofuran

Regulation (EC) No 1935/2004 of the European parliament and of the council of 27 October 2004 on materials and articles intended to come into contact with food and repealing Directives 80/590/EEC and 89/109/EEC. OJ L 338, 13.11.2004, p. 4--17.

In relation to both EFSA‐Q‐2017‐00495 and EFSA‐Q‐2017‐00412.

In relation to EFSA‐Q‐2017‐00495.

In relation to EFSA‐Q‐2017‐00412.

[^1]: Member of the former Working Group on "Food Contact Materials" of the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF).
